A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9

PURPOSE: AT04A and AT06A are two AFFITOPE® peptide vaccine candidates being developed for the treatment of hypercholesterolemia by inducing proprotein convertase subtilisin/kexin type 9 (PCSK9)-specific antibodies. This study aimed to investigate safety, tolerability, antibody development, and reduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeitlinger, Markus, Bauer, Martin, Reindl-Schwaighofer, Roman, Stoekenbroek, Robert M., Lambert, Gilles, Berger-Sieczkowski, Evelyn, Lagler, Heimo, Oesterreicher, Zoe, Wulkersdorfer, Beatrix, Lührs, Petra, Galabova, Gergana, Schwenke, Carsten, Mader, Robert M., Medori, Rossella, Landlinger, Christine, Kutzelnigg, Alexandra, Staffler, Günther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440313/
https://www.ncbi.nlm.nih.gov/pubmed/33969434
http://dx.doi.org/10.1007/s00228-021-03149-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440313/
https://www.ncbi.nlm.nih.gov/pubmed/33969434
http://dx.doi.org/10.1007/s00228-021-03149-2

Ejemplares similares